Last reviewed · How we verify
biosimilar insulin glargine
Biosimilar insulin glargine is a long-acting basal insulin that binds to insulin receptors on cells to promote glucose uptake and lower blood glucose levels.
Biosimilar insulin glargine is a long-acting basal insulin that binds to insulin receptors on cells to promote glucose uptake and lower blood glucose levels. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.
At a glance
| Generic name | biosimilar insulin glargine |
|---|---|
| Also known as | Basaglar |
| Sponsor | Life for a Child Program, Diabetes Australia |
| Drug class | Long-acting basal insulin |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Insulin glargine is a recombinant human insulin analog designed to provide steady, long-acting glycemic control over approximately 24 hours. It binds to insulin receptors on muscle, fat, and liver cells, facilitating glucose uptake and storage while suppressing hepatic glucose production. As a biosimilar, it is a biologically equivalent version of the reference insulin glargine product, manufactured through recombinant DNA technology.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Injection site reactions
- Weight gain
- Lipodystrophy
Key clinical trials
- Impact of Introducing Basaglar Insulin to the Treatment Regimen of Youth With Diabetes in Pakistan (PHASE4)
- Evaluating the Impact of Introducing Basaglar, a Long-acting Analog Insulin, on Clinical and Quality of Life Outcomes in Youth with Diabetes in Bangladesh (PHASE4)
- Introducing Biosimilar Insulin Glargine to the Treatment Regimen of Children and Youth with Type 1 Diabetes in Mali (PHASE4)
- A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to "Standard of Care" Basal Insulins in Insulin Naïve Patients Initiating Insulin (PHASE4)
- A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to "Standard of Care" Basal Insulin in Patients Already Using Basal Insulin (PHASE4)
- Descriptive Analysis of Long- and Intermediate-Acting Insulin in Adult Diabetics
- The Effect of Soliqua on Glucose Variability in Type 2 Patients Among South Asians (PHASE4)
- The Efficacy, Safety, and Immunogenicity Study Comparing an Insulin Glargine Biosimilar Sansulin Log-G to Lantus (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- biosimilar insulin glargine CI brief — competitive landscape report
- biosimilar insulin glargine updates RSS · CI watch RSS
- Life for a Child Program, Diabetes Australia portfolio CI